Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Muraglitazar Coadministered with Insulin in Type 2 Diabetes
NCT00130806Phase 3Terminated
- Sponsor
- Merck & Co.
- Start
- Sep 2005
- Primary completion
- Nov 2005
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of muraglitazar in type 2 diabetes mellitus (T2DM), sponsored by Merck & Co.. Started Sep 2005; status: terminated.
02
Drugs
muraglitazar
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00130806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00130806.